Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 30Gastrointestinal 10Thoracic 7Tumor-Agnostic 5Head & Neck 4Dermatologic 4Endocrine 3CNS 3Sarcoma 2Other solid neoplasm 2Gynecologic 2Other hematologic neoplasm 1NET 1Myeloid 1Lymphoid 1Breast 1

Conditions

Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Carcinoid Tumor 1

Interventions

Everolimus 25Magnetic Resonance Spectroscopy 13pembrolizumab 12pasireotide 12Sunitinib 11Octreotide 11lanreotide 10cabozantinib 10lenvatinib 8Sorafenib 8Cisplatin 8Temozolomide 7Etoposide 7Bevacizumab 7pazopanib 6Paclitaxel 6Nivolumab 6Doxorubicin 6Carboplatin 6Capecitabine 6vandetanib 5gallium Ga 68 dotatate 5Specimen Handling 5trametinib 4lutetium Lu 177 dotatate 4dabrafenib 4Mitotane 4Iodine-131 4telotristat ethyl 3surufatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Axitinib × Endocrine × Clear all
NCT01744249 2026-04-28

Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Grupo Espanol de Tumores Neuroendocrinos

Phase 2/3 Completed
256 enrolled 25 charts
EndocrineNET

Neuroendocrine Tumors

NCT01967576 2021-01-06

Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
14 enrolled 12 charts
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT01435122 2018-10-02

A Study of Axitinib in Advanced Carcinoid Tumors

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
30 enrolled 10 charts
Endocrine

Carcinoid Tumor, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡